TP53 and cancer: Indeed, available genomic landscape studies in ACC indicate a dominance of p53 mutations (present in over half of patients) yet with a variety of mutations with therapies currently in development in other cancers.69,70 For instance, around 20% of patients with ACC have CTNNB1 mutations, which promotes Wnt signaling.